This study, funded by BARDA, is to test the safety and immune response of H5 flu vaccines. The flu vaccine is an inactivated monovalent influenza vaccine, meaning it targets one type of flu virus and is not live. The study uses different doses of the vaccine and tests them with substances called adjuvants (AS03 or MF59) that help the body build a better immune response. The study is randomized (participants are randomly assigned to different groups) and double-blind (neither participants nor most researchers know which group gets which treatment) to ensure fair results.

• This study lasts until Day 203 and includes several visits and tests to check for safety and immune response.
• Participants will receive two doses of the flu vaccine 21 days apart.
• There are specific eligibility rules, such as age and health conditions, to join the study.

Safety checks include looking for side effects like soreness or fever after getting the vaccine. The study aims to see how well the vaccine works by measuring things like seroprotection rate (how much it protects you) and seroconversion rate (how many people develop a protective immune response). If you are healthy, over 18, and meet the criteria, you might consider participating. Compensation details are not mentioned, so check with the study coordinators for more information.